Simposio de La Roche-Posay en el Congreso Mundial IMCAS 2024
Feb. 2024
LA ROCHE-POSAY EN IMCAS 2024
IMCAS 2024: Hiperpigmentación: Resultados clínicos con lo último de La Roche-Posay
Ya puedes ver a la Dra. Delphine KEROB en el Congreso Mundial IMCAS 2024 mientras presenta los resultados clínicos de nuestro nuevo suero MELA B3 para trastornos de hiperpigmentación.
Presented Posters
Discovery of 2-mercapto nicotinoyl glycine
A new potent skin lightening agent with a proven clinical efficacy
Melanin production inhibitors currently marketed tyrosinase, the rate limiting enzyme in melanin synthesis process. Yet only a few have demonstrated clinical efficacy while some present safety issues.
2-Mercaptonicotinoyl glycine: a new molecule that prevents and decreases uv-induced pigmentation.
Hyperpigmentation disorders are a frequent reason for dermatology consultations as they can impair quality of life.
A topical formula containing proxylane and niacinamide augments the anti-ageing benefits of a non-ablative laser treatment
Minimally invasive aesthetic procedures, such as microneedling and non-ablative laser treatment, are rapidly increasing in popularity due to minimal recovery and downtime with effective results for skin rejuvenation.
Pigmentary disorders, prevalence, impact on quality of life, social stigmatization: Results of the first large international survey
Pigmentary disorders (PD) such as Melasma, Post-inflammatory Hyperpigmentation (PIH), Solar Lentigo, Peri-Orbital Hyperpigmentation (POH) and Axillary Hyperpigmentation (AH) are frequent dermatological conditions, but little is known on their real-world prevalence and impact.